Review Article
Interstitial Lung Disease in Rheumatoid Arthritis in the Era of Biologics
Table 2
Number and percentage of RA patients presenting ILD under anti-TNFα treatment.
| Total no. of RA patients | Patients developing ILD | References | anti-TNFα N/% | Infliximab N/% | Etanercept N/% | Adalimumab N/% |
| 10.649 | 299 (2.8%) | UN | UN | UN | Dixon et al., 2010 [26] |
| 13.894 | 77(0.6%) | UN | 77 (0.6%) | UN | Koike et al., 2011 [27] |
| 5.000 | 25(0.5%) | UN | 25 (0.5%) | UN | Takeuchi et al., 2008 [28] |
|
|
ILD: interstitial lung disease; UN: unavailable.
|